Fasenra cleared for Hypereosinophilic Syndrome

What this means

Fasenra is an antibody treatment that targets a protein receptor involved in eosinophil production, reducing high levels of these immune cells that can cause tissue damage. Today FDA approved Fasenra for hypereosinophilic syndrome, a rare condition where excess eosinophils lead to inflammation and organ problems. This decision expands treatment options for patients aged 12 and older who have this condition without a known underlying cause.